Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/3 cls

Amgen Inc. (NASDAQ:AMGN)

Jefferies

Eun Yang

Other

Buy

-2%

$106.48

Yang maintained her buy rating after issuing a note with initial data from eight patients with homozygous familial hypercholesterolemia (hoFH) from Part A of the Phase II/III TESLA trial evaluating AMG-145. Specifically, monthly subcutaneous injections of the human mAb against proprotein convertase subtilisin/kexin type 9 (PCSK9) led to a 17% mean reduction in LDL-C from baseline to week 12. Patients then received AMG 145 every two weeks for an additional 12 weeks, which led to a 19% reduction in LDL-C from baseline to week 16. Wang expects 12-week data for the twice-monthly arm to be presented at the European Atherosclerosis Society meeting in June in Lyon. AMG 145 is in Phase III for various endocrine/metabolic conditions.